Breathless and Dismissed: How G6PD Deficiency Gets Mistaken for Anxiety and Panic Disorder

Imagine sitting in an emergency room, your heart hammering against your ribs, your lungs struggling to draw a full breath, your head swimming with dizziness you cannot explain. A nurse takes your vitals, a physician reviews your chart, and within minutes you are handed a referral to a mental health provider. No blood panel for hemolysis. No inquiry about recent medications or foods. Just a diagnosis of anxiety—and a quiet, unspoken suggestion that the problem is in your head.

For a significant number of people living with glucose-6-phosphate dehydrogenase (G6PD) deficiency, that scenario is not hypothetical. It is a lived reality that repeats itself across emergency departments, primary care offices, and urgent care clinics throughout the United States. The consequences range from unnecessary psychiatric treatment to dangerously delayed care for a condition that, left unaddressed, can escalate into life-threatening hemolytic anemia.

Why the Symptoms Overlap So Convincingly

G6PD deficiency impairs the red blood cell's primary defense against oxidative stress. When a triggering agent—certain medications, fava beans, infections, or even some common household chemicals—floods the body with oxidative compounds, red blood cells begin to rupture in a process called hemolysis. The body responds to this sudden loss of oxygen-carrying capacity with a cascade of compensatory reactions: the heart accelerates to circulate the remaining healthy cells more rapidly, the respiratory rate climbs as the lungs attempt to deliver more oxygen, and the brain, starved of adequate perfusion, generates sensations of lightheadedness, unreality, and impending doom.

That cluster of sensations—palpitations, shortness of breath, dizziness, trembling, and a pervasive sense of dread—maps almost perfectly onto the Diagnostic and Statistical Manual's criteria for a panic attack. A clinician who has never encountered a hemolytic episode, or who is not actively considering a hematologic cause, will understandably pattern-match to the more familiar psychiatric diagnosis. The problem is not negligence so much as it is a knowledge gap compounded by time pressure and the sheer rarity of G6PD-related presentations in many clinical settings.

The Diagnostic Detour and Its Costs

Patients who receive an anxiety or panic disorder label in place of a G6PD diagnosis frequently describe years of misaligned treatment. Anti-anxiety medications are prescribed. Cognitive behavioral therapy is recommended. Some patients genuinely wonder whether they are imagining their physical symptoms. Meanwhile, the underlying enzymatic deficiency goes unaddressed, and the next exposure to a trigger can produce another crisis—sometimes more severe than the last.

There is also a subtler cost that is harder to quantify: the erosion of trust between patient and provider. When a person has been told repeatedly that their physical distress is psychological, they often begin to self-censor in clinical encounters, minimizing symptoms or hesitating to seek care promptly. That hesitation can be dangerous when a true hemolytic crisis requires urgent intervention.

The diagnostic detour is particularly pronounced among demographic groups in whom G6PD deficiency is most prevalent—African American, Mediterranean, Middle Eastern, and Southeast Asian populations—communities that already face well-documented disparities in how physical symptoms are evaluated and taken seriously within the American healthcare system.

Recognizing the Distinguishing Features

While a definitive diagnosis requires laboratory confirmation, certain clinical features can help distinguish a hemolytic episode from a primary anxiety disorder. Patients and their advocates should be aware of these markers when preparing for medical appointments.

Jaundice and scleral icterus. The breakdown of red blood cells releases bilirubin into the bloodstream. A yellowish tint to the skin or the whites of the eyes during or after an episode is a meaningful indicator that something hematologic may be occurring.

Dark or tea-colored urine. Hemoglobinuria—the presence of hemoglobin in the urine from ruptured cells—produces a characteristic darkening that is not associated with anxiety disorders.

Pallor and fatigue disproportionate to activity. The profound exhaustion following a hemolytic episode often persists for days and is qualitatively different from the post-adrenaline fatigue that follows a panic attack.

A clear precipitating exposure. If symptoms arise within hours of taking a new medication, consuming fava beans, or experiencing an acute infection, a hemolytic trigger should be strongly considered before a psychiatric explanation is accepted.

Advocating for the Right Evaluation

Patients who suspect their episodes may be hemolytic rather than psychiatric have both the right and the responsibility to ask for specific diagnostic workup. The following strategies have proven effective for members of the G6PD community navigating this challenge.

Request a complete blood count with differential and a reticulocyte count. During or shortly after a hemolytic episode, these tests will typically reveal a drop in hemoglobin, an elevated reticulocyte count indicating compensatory red cell production, and possibly an elevated bilirubin level. Bringing these requests to an appointment in writing—rather than relying on verbal communication alone—increases the likelihood they will be ordered.

Ask specifically about G6PD enzyme activity testing. This test is not part of a standard metabolic panel and must be explicitly requested. It is worth noting that testing during or immediately after an acute crisis can yield a falsely normal result, because the most enzyme-deficient cells have already been destroyed. A follow-up test several weeks after recovery provides a more accurate picture.

Bring a written symptom timeline. Document every episode with dates, duration, associated symptoms, and any potential triggers consumed or encountered in the preceding 24 to 72 hours. A pattern of episodic physical symptoms linked to specific exposures is far more consistent with G6PD-related hemolysis than with a primary anxiety disorder.

Seek a hematologist referral if primary care evaluation is inconclusive. Hematologists are specifically trained to evaluate red cell disorders and are more likely to recognize the clinical picture of G6PD deficiency than a general practitioner who may see only one or two such cases in an entire career.

Bring supporting literature to appointments. Peer-reviewed resources and patient advocacy materials from organizations like the National Organization for Rare Disorders (NORD) can help frame the conversation without it feeling adversarial. Presenting clinical evidence invites collaboration rather than conflict.

Reframing the Narrative

The misdiagnosis of G6PD deficiency as anxiety is not simply a medical inconvenience—it is a patient safety issue with real clinical stakes. Every month spent pursuing an incorrect psychiatric diagnosis is a month during which the patient remains unprotected from triggers, uninformed about safe medication choices, and vulnerable to a potentially severe hemolytic crisis.

Empowerment in this context means arriving at every clinical encounter prepared: with documentation, with specific questions, and with the confidence to politely but firmly request a physical explanation before accepting a psychological one. It also means connecting with peer communities—online support groups, patient advocacy networks, and resources like this one—where others who have navigated the same diagnostic maze can offer guidance drawn from direct experience.

The symptoms you are experiencing are real. The condition causing them is real. And the knowledge that can lead to an accurate diagnosis is available—sometimes, it simply needs to be carried into the room by the patient who needs it most.